Physician profile
Samir Rajan
NPI 1174719124
$2,254.98
in general payments reported to CMS, 2019-2025
18 companies · $273 in 2025
The $273 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2020: $235 · 2021: $599 · 2022: $633 · 2023: $245 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $517.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $474.98 | 2019-2023 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $226.58 | 2019-2023 | Jynarque |
| Horizon Therapeutics Plc | $202.23 | 2019-2023 | Krystexxa |
| Fresenius USA Marketing, INC. | $189.47 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $188.38 | 2022-2025 | Purified Cortrophin Gel |
| Opko Pharmaceuticals, LLC | $148.33 | 2020-2023 | Rayaldee |
| Glaxosmithkline, LLC. | $138.14 | 2021-2025 | Benlysta |
| Aurinia Pharma U.S., INC. | $131.79 | 2021-2023 | Lupkynis |
| Vifor Pharma, INC. | $114.87 | 2019-2023 | Korsuva |
| Daiichi Sankyo INC. | $110.89 | 2019-2022 | |
| Calliditas Therapeutics US INC. | $85.05 | 2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $48.53 | 2022-2023 | |
| Travere Therapeutics, INC. | $44.63 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $43.70 | 2022-2023 | Acthar |
| Akebia Therapeutics INC | $39.90 | 2019-2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $37.78 | 2021 | |
| Mallinckrodt Enterprises LLC | $15.71 | 2019 | |
| Alexion Pharmaceuticals, INC. | $14.02 | 2023 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samir Rajan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.